PharmEasy parent rises to unicorn status as TPG Growth, others invest
Advertisement

PharmEasy parent rises to unicorn status as TPG Growth, others invest

By Joseph Rai

  • 07 Apr 2021
PharmEasy parent rises to unicorn status as TPG Growth, others invest
Credit: 123RF.com

API Holdings Pvt Ltd, the parent of online firm PharmEasy, on Wednesday said it has raised $350 million (about Rs 2,566 crore) from Prosus Ventures, TPG Growth and others as part of its Series E round. 

Existing investors Temasek, CDPQ, LGT Lightrock, Eight Roads and Think Investments also participated in this round, said API Holdings in a statement. 

Of the total amount raised in the round, API Holdings has closed primary and secondary funding worth $323 million. The balance will be closed soon. 

Advertisement

The round values the company at $1.2 billion, propelling it into the unicorn club.

In November last year, VCCircle reported that TPG Growth was set to pick up a 7% stake in what would be its debut investment in a digital healthcare platform in the country. 

Prosus Ventures is the investment arm of South African internet and media conglomerate Naspers. It has been a prolific investor across sectors in India’s startup ecosystem, with bets including edtech firm Eruditus, social commerce platform Meesho, and food delivery unicorn Swiggy. 

Advertisement

Earlier this year, it also invested in agri-tech startup DeHaat. 

TPG Growth had previously invested directly in medical devices maker Healthium MedTech (formerly Sutures India), which it sold to Apax Partners in 2018. Its parent TPG has a stake in Manipal Hospitals. 

PharmEasy was founded in 2015 by Dharmil Sheth and Dhaval Shah as a subsidiary of Ascent Health. It raised around $5 million in its Series A round in 2016 from Ascent Health, Bessemer Venture Partners, Orios Venture Partners and other investors. 

Advertisement

In March 2017, the company mopped up $16 million in its Series B round. It topped up this round with $2 million the following month. 

In 2018, it raised $30 million from Bessemer and others in a Series C round. In September last year, PharmEasy secured $50 million in an extended Series C round led by new investor Eight Roads Ventures. 

Meanwhile, Ascent Health raised $220 million in a funding round led by new investor Temasek in 2019. 

Advertisement

Ascent Health and PharmEasy merged subsequently and the combined entity brought all the investors under API Holdings. 

In September last year, PharmEasy received antitrust approval to acquire Bengaluru-based Medlife International to mark a small consolidation in the space. 

Advertisement

Share article on

Advertisement
Advertisement